Potassium channel, inward rectifier subfamily J member 11 (KCNJ11)

KCNJ11 encodes the Kir6.2 protein, which serves as the pore-forming subunit of the ATP-sensitive potassium (KATP) channel, primarily located in pancreatic beta cells [1, 3]. This channel plays a critical role in glucose homeostasis by acting as a metabolic sensor that couples the cell's energy state (ATP/ADP ratio) to its electrical activity [7, 8]. When blood glucose levels rise, the resulting increase in intracellular ATP causes the KATP channel to close, leading to membrane depolarization, calcium influx, and the subsequent release of insulin [9]. Mutations in KCNJ11 are linked to several metabolic disorders, including neonatal diabetes mellitus and congenital hyperinsulinism, and common variants like E23K are associated with an increased risk of type 2 diabetes [2, 6]. Pharmacologically, the KATP channel complex is a major therapeutic target; sulfonylureas and meglitinides are used to close the channel and stimulate insulin secretion, while channel openers like diazoxide are employed to treat hyperinsulinism [5, 12]. Understanding the genetic and functional nuances of KCNJ11 is essential for precision medicine, particularly in transitioning patients with specific neonatal diabetes mutations from insulin to oral sulfonylurea therapy [10, 11].

Other names

Kir6.2BIRIKATPHHF2MODY13TNDM3PNDM2PHHI

KCNJ11 forms the pore of the KATP channel complex. Drugs like sulfonylureas and meglitinides bind to the associated SUR1 subunit to induce channel closure, leading to membrane depolarization and insulin secretion. Conversely, KATP channel openers like diazoxide stabilize the open state of the channel, preventing depolarization and inhibiting insulin release.